ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting

    Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?

    Bruno Fautrel1, Thao Pham2, Jacques Morel3, Toni Alfaiate4, Emmanuelle Dernis5, Philippe Gaudin6, Olivier Brocq7, Elisabeth Solau-Gervais8, Jean-Marie Berthelot9, Jean-Charles Balblanc10, Xavier Mariette11 and Florence Tubach12, 1Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, 2Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, 3Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 4Biostatistics, Bichat Hospital, AP-HP, Paris, France, 5Le Mans Hospital, Le Mans, France, 6Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 7Hospital of Princesse Grâce de Monaco, Monaco, France, 8Rheumatology, University Hospital of Poitiers, Poitiers, France, 9Rheumatology Unit, Nantes University Hospital, Nantes, France, 10Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, 11Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 12INSERM, Universite Paris Diderot, Paris, France

    Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
  • Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting

    Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics

    Antonio da Silva1, Ulrich Kronthaler1, Cornelius Fritsch2, Johann Poetzl3, Adelheid Rohde4, Anastassia Papandrikopoulou5, Hans-Peter Hofmann6 and Jan Marinus Visser1, 1Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, 2Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland, 3Bioanalytics, Sandoz Biopharmaceuticals/Hexal AG, Oberhaching, Germany, 4Characterisation, Sandoz Biopharmaceuticals/Hexal AG, Kundl, Austria, 5Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, 6Pre-clinical, Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany

    Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…
  • Abstract Number: 1413 • 2013 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study

    Edward Keystone1, Robert Landewé2, Ronald van Vollenhoven3, Bernard Combe4, Vibeke Strand5, Philip J. Mease6, Laura Shaughnessy7, Brenda VanLunen7 and Désirée van der Heijde8, 1University of Toronto, Toronto, ON, Canada, 2Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, 3Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 4Montpellier University Hospital, Montpellier, France, 5Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 6Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 7UCB Pharma, Raleigh, NC, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: In the RAPID1 randomized controlled trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements…
  • Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting

    Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis

    Agnes Szentpetery1, Mark Kilbane2, Myra P. O'Keane2, Muhammad Haroon3, Phil Gallagher4, Susan van der Kamp5, Malachi McMenna6 and Oliver FitzGerald3, 1Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Metabolism Laboratory, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 3Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 4Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 5DXA Unit, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 6Department of Endocrinology & Metabolic Bone Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland

    Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…
  • Abstract Number: 2483 • 2013 ACR/ARHP Annual Meeting

    Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry

    Agnes Szentpetery1, Muhammad Haroon2, Phil Gallagher3, Eric J. Heffernan4 and Oliver FitzGerald2, 1Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 4Radiology, St. Vincent's University Hospital, Dublin, Ireland

    Background/Purpose: Hand bone loss is an early feature in both RA and PsA, but there is less data available on periarticular bone gain, in particular…
  • Abstract Number: 1799 • 2013 ACR/ARHP Annual Meeting

    Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

    Robert B. M. Landewé1, Martin Rudwaleit2, Désirée M. van der Heijde3, Maxime Dougados4, Philip Mease5, John D. Reveille6, Jessica Walsh7, Alan J. Kivitz8, Walter P. Maksymowych9, Jürgen Braun10, Atul A. Deodhar11, Christian Stach12, Bengt Hoepken12, Pritibha Singh12 and Joachim Sieper13, 1Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 2Endokrinologikum Berlin, Berlin, Germany, 3Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 5Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, 6Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 7Rheumatology, University of Utah Hospital, Salt Lake City, UT, 8Altoona Center for Clinical Research, Duncansville, PA, 9Medicine, University of Alberta, Edmonton, AB, Canada, 10Rheumazentrum Ruhrgebiet, Herne, Germany, 11Div of Arthritis & Rheum OP-09, Oregon Health & Science University, Portland, OR, 12UCB Pharma, Monheim, Germany, 13Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany

    Background/Purpose: Previous reports of RAPID-axSpA have demonstrated the efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in patients (pts) with axial spondyloarthritis…
  • Abstract Number: 1363 • 2013 ACR/ARHP Annual Meeting

    Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis -a 7-Year Retrospective Observational Study

    Minkyung Kwon1, Mindong Sung1, Yong-Jin Kwon1, Young Goo Song1, Sang-Won Lee2, Min-Chan Park1, Yong-Beom Park1, Soo-Kon Lee1 and Jason Jungsik Song1, 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea

    Background/Purpose: Active tuberculosis (TB) risk increases during anti-tumor necrosis factor (TNF) therapy and latent TB infection (LTBI) screening is recommended in potential TNF inhibitor users.…
  • Abstract Number: 326 • 2013 ACR/ARHP Annual Meeting

    Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol

    Arthur Kavanaugh1, Dafna D. Gladman2, Désirée M. van der Heijde3, Oana Purcaru4 and Philip J. Mease5, 1Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4UCB Pharma, Brussels, Belgium, 5Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there…
  • Abstract Number: 2486 • 2013 ACR/ARHP Annual Meeting

    Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers

    Carina M F Gomes1, Maria Teresa Terreri2, Maria Isabel Pinto3, Karen Oseki3, Fernanda Spina4 and Marcelo M. Pinheiro5, 1Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, 3Pediatrics, Universidade Federal de São Paulo, Sao Paulo, Brazil, 4Rheumatology Division, Universidade Federal de São Paulo Unifesp/EPM, Brazil, Universidade Federal de São Paulo, Sao Paulo, Brazil, 5Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

    Background/Purpose: About 5% of the Brazilian population has some chronic inflammatory arthropathy (CIA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA) and juvenile…
  • Abstract Number: 1697 • 2013 ACR/ARHP Annual Meeting

    Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?

    Elizabeth V. Arkema1, Jerker Jonsson2, Eva Baecklund3, Maud Rutting4, Judith Bruchfeld5, Nils Feltelius4 and Johan Askling1,6, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Swedish Institute for Communicable Disease Control, Solna, Sweden, 3Department of Medical Sciences, Rheumatology, Uppsala University Hospital, Uppsala, Sweden, 4Swedish Medical Products Agency, Uppsala, Sweden, 5Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, 6Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose:   Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which…
  • Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting

    Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry

    ŽIga Rotar1 and Matija Tomsic2, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia

    Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
  • Abstract Number: 313 • 2013 ACR/ARHP Annual Meeting

    The DC-STAMP+IL17A+ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy

    Yahui Grace Chiu1, Edward M. Schwarz2, Hua He3, Francisco A. Tausk4, Sharon Moorehead5, Michelle Smith5 and Christopher T. Ritchlin5, 1Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Biostatistics and Computational Biology, University of Rochester, Rochester, NY, 4Dermatology, University of Rochester, Rochester, NY, 5Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop psoriatic arthritis (PsA), a potentially destructive joint disease, within 10 years of Ps onset. Although early diagnosis…
  • Abstract Number: 2455 • 2013 ACR/ARHP Annual Meeting

    The Lipid Profile Improves In Patients With Ankylosing Spondylitis Responding To TNF Blocking Therapy

    Sjoerd C. Heslinga1,2, Irene E. Van der Horst-Bruinsma3,4, Alper M. van Sijl2,3 and Michael T Nurmohamed1,5, 1Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 3Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 4Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 5VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular risk. Cardiovascular risk factors such as smoking, dyslipidemia, overweight,…
  • Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting

    Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis

    Nisha Nigil Haroon1, Jeevitha Srighanthan2, Nayef AL Ghanim3, Robert D. Inman4,5,6,7,8,9 and Angela Cheung10, 1Medicine, University of Toronto, Toronto, ON, Canada, 2Osteoporosis Program, University of Toronto, Ontario, ON, Canada, 3Rheumatology, University of Toronto, Toronto, ON, Canada, 4Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada, 7Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 8U of Toronto, Toronto, ON, Canada, 9Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 10Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
  • Abstract Number: 1351 • 2013 ACR/ARHP Annual Meeting

    A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)

    Yoon-Kyoung Sung1,2, Soo-Kyung Cho1,2, Chan-Bum Choi3,4, Soyoung Won5, So-Young Bang6, Hoon-Suk Cha7, Jung-Yoon Choe8, Won Tae Chung9, Seung-Jae Hong10, Jae-Bum Jun4, Hyoun Ah Kim11, Jinseok Kim12, Seong-Kyu Kim8, Tae-Hwan Kim4, Hye-Soon Lee13, Jaejoon Lee7, Jisoo Lee14, Shin-Seok Lee15, Sung Won Lee16, Yeon-Ah Lee10, Seong-Su Nah17, Chang-Hee Suh18, Dae-Hyun Yoo4, Bo Young Yoon19 and Sang-Cheol Bae1,2, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 5Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Hanyang University Guri Hospital, Guri, South Korea, 7Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 8Catholic University of Daegu School of Medicine, Daegu, South Korea, 9Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, 10Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, 11Ajou University Hospital, Suwon, South Korea, 12Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, 13Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, 14Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, 15Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, 16Rheumatology, Dong-A University Hospital, Busan, South Korea, 17Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, 18Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, 19Inje University Ilsan Paik Hospital, Goyang, South Korea

    Background/Purpose: The results from RCTs may not be generalizable to clinical practice because of their inclusion and exclusion criteria. Instead, observational cohorts and registries might…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology